Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

Next Up for ‘Moving Mountains for Multiple Myeloma’ — Patagonia

With the goal of encouraging the multiple myeloma community while raising money to advance treatments, Moving Mountains for Multiple Myeloma (MM4MM) is gearing up for its next expedition — Patagonia. The Nov. 9–19 excursion will take participants across the picturesque, but often-rugged, terrain of the region at the southern end of…

‘Moving Mountains for Multiple Myeloma’ Takes Trek Challenge to Iceland

Aiming to both inspire the multiple myeloma community and raise money to accelerate treatments, members of Moving Mountains for Multiple Myeloma (MM4MM) recently traversed Iceland’s impressive landscape. The 14-member excursion included two patients plus caregivers, family members, myeloma specialists, and individuals from organizing partners. The MM4MM initiative is a…

AJMC Introduces 14-part Video Series on Multiple Myeloma Treatment

A new video series by the American Journal of Managed Care (AJMC) features experts discussing issues related to multiple myeloma treatment. Called “A Review of the Treatment for Multiple Myeloma,” the 14-part educational series is the AJMC’s latest panel discussion. “During this educational video series, our panel…

MMRF Launches ‘Immune Atlas’ Aiming for Tailored Myeloma Treatments

To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative. Called Immune Atlas, the pilot aims to establish a “gold standard” immune profiling platform for multiple myeloma research studies, and to produce the…

Myeloma UK Launches Research Program Focused on Trial Design

In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research program. Called the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Program (UKMRA-Myeloma UK-CARP), the grant initiative seeks to build upon the success of…

MMRF Launches CureCloud Data Hub to Identify Treatment Targets

Addressing the need for shared, comprehensive data to identify targets and provide personalized treatment road maps, the Multiple Myeloma Research Foundation (MMRF) is launching a centralized data hub called MMRF CureCloud. Designed to ultimately speed delivery of precision medicine to people with multiple myeloma, CureCloud is…

OncLive Poised to Induct 2019 Class of ‘Giants of Cancer Care’

OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in Chicago, Illinois. Inductees are being recognized for furthering the field of oncology, including multiple myeloma, through research and clinical practices. “We are looking forward to honoring…

bluebird bio Opens Manufacturing, Research Facility in Durham, N.C.

Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including the CAR T-cell therapies bb2121 and bb21217 for relapsed or refractory multiple myeloma. Some 50 researchers, engineers and others are employed at the 125,000-square-foot…